Why Baby Bunting, Northern Star, Oil Search, & Telix shares are storming higher

Baby Bunting Group Ltd (ASX:BBN) and Northern Star Resources Ltd (ASX:NST) shares are two of four storming higher on Tuesday…

stock growth chart

Image source: Getty Images

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is dropping lower and on course to end its winning streak. The benchmark index is currently down 0.4% to 5,917.6 points.

Four shares that have not let that hold them back today are listed below. Here's why they are storming higher:

The Baby Bunting Group Ltd (ASX: BBN) share price is up 6% to $1.74. Investors have been buying the baby products retailer's shares after the release of a trading update this morning. According to the release, Baby Bunting's FY 2021 comparable store sales growth to 2 October was 17%. Excluding its stores in the Melbourne metropolitan region, its comparable store sales would have been up 28.5%.

The Northern Star Resources Ltd (ASX: NST) share price has jumped 7% higher to $14.81 after announcing a merger with Saracen Mineral Holdings Limited (ASX: SAR). Management notes that the merger will create a top 10 global gold company targeting production of 2 million ounces of gold per annum exclusively in tier-1 locations. It also expects the merger to result in unique pre-tax synergies of $1.5 billion to $2 billion.

The Oil Search Limited (ASX: OSH) share price is up almost 4% to $2.81. The catalyst for this was a strong rebound in oil prices overnight. Prices jumped higher amid a combination of COVID-19 stimulus hopes and production disruption in Norway. The S&P/ASX 200 Energy index is up 1.7% at the time of writing.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has stormed almost 6% higher to $1.74. This follows an announcement which revealed that the clinical-stage biopharmaceutical company's 18F-FET product has been granted Orphan Drug Designation for the positron emission tomography (PET) imaging of glioma by the US FDA. The granting of this designation qualifies Telix for various drug development incentives. These could include FDA-administered market exclusivity for seven years and waived FDA prescription drug user fees.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Multi-ethnic people looking at a camera in a public place and screaming, shouting, and feeling overjoyed.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a strong hump day on the ASX today.

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a wild, but ultimately positive, Tuesday for investors.

Read more »

Rocket going up above mountains, symbolising a record high.
Share Gainers

Invested $5,000 in Dateline shares a week ago? Here's how much you'd have now

It's been a huge week for Dateline shares.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy start to the week's trading today.

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a sour end to the trading week for investors this Friday.

Read more »

Drone flying in the sky.
Share Gainers

EOS shares jump 7% as ASX 200 falls. Could $15 be next?

Could this ASX defence stock have much further to run?

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough Thursday for investors this session.

Read more »

AI microprocessor on motherboard computer circuit.
AI Stocks

If I'd invested $5,000 in this ASX AI stock 6 months ago, I'd have $113,750 today!

Up 2,175% in six months, this ASX AI stock is forecast to keep charging higher. But why?

Read more »